Flublok influenza vaccine more effective than current flu shot
The study compared the traditional, quadrivalent, inactivated and egg-based vaccine with Flublok Quadrivalent. The results suggest that Flublok is superior due to fewer people reporting catching the flu after they received the Flublok Quadrivalent vaccine.
The study involved approximately 9,000 subjects between the ages of 50 years and older. Half of the subjects received the Flublok Quadrivalent influenza vaccine, while the remaining half received the inactivated, quadrivalent, egg-based influenza vaccine. The data showed 31 percent more subjects received protection from the Flublok compared to the traditional vaccine.
"This study points out the advantages of using modern technology to overcome problems with traditional influenza vaccine manufacturing," Manon Cox, president and CEO of Protein Sciences, said. "Ten years ago, we had the first evidence in clinical trial PSC01 that more antigen was beneficial even for healthy adults. Today with support from the Biomedical Advanced Research and Development Authority (BARDA) we were able to show statistically significant better performance than traditional egg-produced vaccines."
The company’s representatives presented the clinical trial results.